Luis González‐González

ORCID: 0000-0002-5853-967X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • Microbial infections and disease research
  • Animal Virus Infections Studies
  • Innovations in Medical Education
  • Reproductive tract infections research
  • SARS-CoV-2 detection and testing
  • Ethics in medical practice
  • Bacteriophages and microbial interactions
  • Ocular Diseases and Behçet’s Syndrome
  • Streptococcal Infections and Treatments
  • vaccines and immunoinformatics approaches
  • Viral gastroenteritis research and epidemiology
  • Plant Virus Research Studies
  • Genital Health and Disease
  • Vasculitis and related conditions
  • Bartonella species infections research
  • Aquaculture disease management and microbiota
  • Anesthesia and Pain Management
  • Occupational Health and Safety in Workplaces
  • Surgical Simulation and Training
  • Business, Innovation, and Economy
  • Ocular Oncology and Treatments
  • Clinical Reasoning and Diagnostic Skills
  • Cervical Cancer and HPV Research
  • Magnesium in Health and Disease

Clínica Girona
2022-2025

Hospital Sant Joan de Déu Barcelona
2024

Universitat Autònoma de Barcelona
2014-2020

Harvard University
2013-2016

VA Boston Healthcare System
2016

MetroWest Medical Center
2015

Creedmoor Psychiatric Center
2014

Massachusetts Eye Research and Surgery Institute
2011-2012

Ocular Immunology and Uveitis Foundation
2011

Tecnológico de Monterrey
2010

A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of IIb HH-2, where immunogenicity safety heterologous booster with PHH-1V is assessed versus homologous BNT162b2 at 14, 28 98 days after vaccine administration. The HH-2 an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority trial, participants...

10.1016/j.lanepe.2023.100613 article EN cc-by-nc-nd The Lancet Regional Health - Europe 2023-04-14

Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and decrease mortality rates. However, SARS-CoV-2 variants are continuously evolving, development new accessible is essential to mitigate the pandemic. Here, we present data on preclinical studies mice receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting an RBD fusion heterodimer comprising B.1.351 B.1.1.7 formulated SQBA adjuvant, oil-in-water...

10.1016/j.isci.2023.106126 article EN cc-by-nc-nd iScience 2023-02-02

The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of PHH-1V adjuvanted recombinant vaccine as heterologous booster against homologous with BNT162b2. Interim results demonstrated strong humoral cellular immune response SARS-CoV-2 Wuhan-Hu-1 strain Beta, Delta, Omicron BA.1 variants up to day 98 post-dosing. Here we report that these responses are sustained 6 months, including in...

10.1016/j.vaccine.2024.126685 article EN cc-by-nc-nd Vaccine 2025-01-13

Functional genomics studies in minimal mycoplasma cells enable unobstructed access to some of the most fundamental processes biology. Conventional transposon bombardment and gene knockout approaches often fail reveal functions genes that are essential for viability, where lethality precludes phenotypic characterization. Conditional inactivation is effective characterizing central cell growth division, but tools limited this purpose mycoplasmas. Here we demonstrate systems inducible...

10.1021/acssynbio.8b00028 article EN publisher-specific-oa ACS Synthetic Biology 2018-05-22

Summary The cell wall‐less bacterium Mycoplasma genitalium uses specialized adhesins located at the terminal organelle to adhere host cells and surfaces. is a polar structure protruding from body that internally supported by cytoskeleton also has an important role in motility. We have engineered M. null mutant for MG491 protein showing massive downstream destabilization of proteins involved organization. This strain exhibited striking similarities with previously isolated MG_218 strain. Upon...

10.1111/mmi.13305 article EN Molecular Microbiology 2015-12-29

Abstract Mycoplasma genitalium is a human pathogen adhering to host target epithelial cells and causing urethritis, cervicitis pelvic inflammatory disease. Essential for infectivity transmembrane adhesion complex called Nap comprising proteins P110 P140. Here we report the crystal structure of P140 both alone in with N-terminal domain P110. By cryo-electron microscopy (cryo-EM) tomography (cryo-ET) find closed open conformations, determined at 9.8 15 Å, respectively. Both structures cryo-EM...

10.1038/s41467-020-16511-2 article EN cc-by Nature Communications 2020-06-08

Mycoplasma genitalium, the causative agent of non-gonococcal urethritis and pelvic inflammatory disease in humans, is a small eubacterium that lacks peptidoglycan cell wall. On surface its plasma membrane major adhesion complex, known as NAP essential for gliding motility organism. Here, we have performed cryo-electron tomography intact cells detergent permeabilized M. genitalium aggregates, providing sub-tomogram averages free cell-attached NAPs respectively, revealing tetrameric complex...

10.1111/mmi.13743 article EN Molecular Microbiology 2017-07-03

SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success vaccine production mass vaccination programs, situation is not still completely controlled, therefore accessible second-generation vaccines are required to mitigate pandemic. We previously developed adjuvanted candidate coded PHH-1V, based on a heterodimer fusion protein comprising RBD domain of two variants. Here, we report data efficacy, safety,...

10.1016/j.isci.2023.107224 article EN cc-by-nc-nd iScience 2023-06-28

Summary The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial to compare the immunogenicity and safety of heterologous booster with PHH-1V adjuvanted recombinant vaccine versus homologous mRNA vaccine. Interim results showed strong humoral cellular immune response against SARS-CoV-2 Wuhan-Hu-1 strain Beta, Delta, Omicron BA.1 variants up day 98 after dosing. Here we report that these responses dosing are sustained 6 months....

10.1101/2024.02.01.24302052 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2024-02-03

Summary The terminal organelle of Mycoplasma genitalium is responsible for bacterial adhesion, motility and pathogenicity. Localized at the cell tip, it comprises an electron‐dense core that anchored to membrane its distal end cytoplasm proximal end. surface also covered with adhesion proteins. We performed cellular cryoelectron tomography on deletion mutants eleven proteins are implicated in building organelle, systematically analyze ultrastructural effects. These data were correlated...

10.1111/mmi.13938 article EN Molecular Microbiology 2018-02-23

Mycoplasma genitalium is an appealing model of a minimal cell and synthetic biology study, it was one the first organisms whose genome fully sequenced chemically synthesized. Despite its usefulness as organism, many genetic tools well established for other microorganisms are not currently available in mycoplasmas. We have developed several vectors to adapt Cre-lox technology engineering M. genitalium, providing all-in-one construct that could be also useful obtain unmarked modifications slow...

10.1093/dnares/dsw015 article EN cc-by-nc DNA Research 2016-04-15

Summary Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and welltolerated in healthy young adults a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of IIb HH-2, where immunogenicity safety heterologous booster with PHH-1V is assessed versus homologous BNT162b2 at 14, 28 98 days after vaccine administration. Methods The HH-2 an ongoing multicentre, randomised, active-controlled, double-blind,...

10.1101/2022.07.05.22277210 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2022-07-05

A number of adherent mycoplasmas have developed highly complex polar structures that are involved in diverse aspects the biology these microorganisms and play a key role as virulence factors by promoting adhesion to host cells first stages infection. Attachment activity mycoplasma has been traditionally investigated determining their hemadsorption ability red blood it is distinctive trait widely examined when characterizing different species. Despite fact protocols qualitatively determine or...

10.1371/journal.pone.0087500 article EN cc-by PLoS ONE 2014-01-30

Mycoplasma hyopneumoniae is a prokaryotic pathogen that colonizes the respiratory ciliated epithelial cells in swine. Infected animals suffer lesions, causing major economic losses porcine industry. Characterization of immunodominant membrane-associated proteins from M. may be instrumental development new therapeutic approaches. Here, crystal structure P46, one main surface-antigen proteins, presented and shows N- C-terminal α/β domains connected by hinge. The structures solved this work...

10.1107/s2059798320003903 article EN Acta Crystallographica Section D Structural Biology 2020-04-15

requerimientos económicos, políticos y sociales de la comunidad. Sin embargo, en el ámbito las profesiones relacionadas con salud, dicho concepto trasciende este entorno al entrar juego perspectiva ética que, idealmente, profesional salud antepone los intereses demás a propios. De esta manera, profesión médica se convierte una forma vida regida por principios éticos guiada más altos estándares profesionalismo, constituyéndose vocación no simple ocupación. Para devolver su distintiva, es...

10.5294/pebi.2010.14.1.2 article ES cc-by Persona y Bioética 2010-06-01

Summary Current C0VID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease and decrease mortality rates. However, SARS-CoV-2 variants are continuously evolving, development new accessible COVID-19 is essential to mitigate the pandemic. Here, we present data on preclinical studies mice receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting an RBD fusion heterodimer comprising B.1.351 B.1.1.7 formulated SQBA adjuvant,...

10.1101/2021.11.22.469117 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2021-11-23

Study Design. Randomized clinical trial. Objective. To compare the effect on quality of life night-time (NT) and full-time (FT) brace treatment for adolescent idiopathic scoliosis (AIS). Summary Background Data. Conservative (AIS) with braces has proven to prevent risk progression need surgery, an inversely proportional relationship number hours worn. However, therapeutic adherence its continue pose a challenge. Materials Methods. Open-label trial including AIS patients curves between 25-45...

10.1097/brs.0000000000005228 article EN Spine 2024-12-04

Objectives This study examined the recent trend in use and costs of antineoplastic agents for treatment eye malignancies Taiwan from 2009 to 2012. We also forecasted targeted therapies up including year 2016 based on current patterns. Design Retrospective observational focusing usage malignancy. Setting The monthly claims data malignancy-related were retrieved Taiwan's National Health Insurance Research Database (2009–2012). Main outcome measures calculated number prescriptions each class...

10.1136/bmjopen-2015-010706 article EN cc-by-nc BMJ Open 2016-05-01

SUMMARY SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success vaccine production mass vaccination programmes, situation is not still completely controlled, therefore accessible second-generation vaccines are required to mitigate pandemic. We previously developed adjuvanted candidate coded PHH-1V, based on a heterodimer fusion protein comprising RBD domain of two variants. Here, we report data efficacy,...

10.1101/2022.12.13.520255 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2022-12-13
Coming Soon ...